TVTX (US) share price forecast & AI signal — Travere Therapeutics, Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in TVTX
Travere Therapeutics, Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a BUY with high confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Travere Therapeutics, Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate,...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $49.60 |
| 2026-11-05 | $48.87 |
| 2026-11-04 | $52.42 |
| 2026-11-03 | $49.41 |
| 2026-11-02 | $49.26 |
| 2026-10-30 | $50.39 |
| 2026-10-29 | $50.57 |
TVTX FAQ
Is Travere Therapeutics, Inc (TVTX) a buy or sell this week?
The ACE Stock Bots machine-learning model rates TVTX a BUY for the week of 2026-10-30 with high confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for TVTX?
Every week the model scores TVTX across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.